Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma

ConclusionsRegorafenib improved DFS without an excessively negative effect on QoL. Progressing development to the phase III setting is warranted.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research